Metastatic Renal Cancer Clinical Trial
Official title:
Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma
The purpose of this study is the evaluation of dynamic contrast-enhanced CT (Perfusion-CT)
for therapeutic response predicition in patients with metastasized renal carcinoma (mRCC)
undergoing antiangiogenetic therapy (AAT) with multikinase inhibitors.
In this study patients with mRCC under AAT will be examined with 3 serial Perfusion - CT
scans - partially intergrated in their regular staging CT scheme - at baseline (before AAT
start), 1 week after AAT as well as 8 weeks after AAT initialization. Thereby selected
intrabdomial or intrathoracic metastases will be monitored longitudinally with perfusion CT.
Pretreament and post-treament perfusion characteristics of the assessed metastatic lesions
will be quantified and correlated with patient outcome.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02479490 -
PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
|
Phase 2 | |
Terminated |
NCT01457131 -
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
|
Phase 1 | |
Terminated |
NCT02837757 -
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
|
N/A | |
Recruiting |
NCT05796973 -
Measuring Oncological Value of Exercise and Statin
|
Phase 3 | |
Recruiting |
NCT03630692 -
Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
|
||
Terminated |
NCT01160445 -
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
|
Phase 2 | |
Recruiting |
NCT04316520 -
Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma
|
N/A | |
Terminated |
NCT01273181 -
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
|
Phase 1/Phase 2 |